コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 MHC/tumor peptide complexes to T cells after intratumoral injection.
2 n nu/nu mouse xenograft models with a single intratumoral injection.
3 gnificantly inhibited tumor growth following intratumoral injection.
4 release of entrapped fluorophores following intratumoral injection.
5 actors that can affect tumor retention after intratumoral injection.
6 ntry into the systemic circulation following intratumoral injection.
7 self-assembles into radionuclide seeds upon intratumoral injection.
8 efficacy in vivo was demonstrated only with intratumoral injection.
9 of virus throughout the tumor mass following intratumoral injection.
10 xpressing MCF7 xenografts in nude mice after intratumoral injection.
11 velopment of 1 for brain cancer treatment by intratumoral injections.
12 ribution of exogenous p53 into gliomas after intratumoral injection and to determine the toxicity of
13 rding to the protocol for the ablation-only, intratumoral injection, and intravenous injection groups
16 iomas revealed peak Rluc activity 36 h after intratumoral injection as determined by coelenterazine i
17 ribute to tumor regression, and they support intratumoral injection as the optimal route for their de
19 affect INGN 007 antitumor efficacy following intratumoral injection, but immunity prevents vector spi
22 of 1 x 10(10) plaque-forming units (pfu) via intratumoral injection for 5 days during week 1 of each
23 YX-015 at a dose of 2 x 10(11) particles via intratumoral injection for either 5 consecutive days (st
25 pread and gene transfer in vivo after direct intratumoral injection in a variety of primary cancer mo
28 it either brief or sustained retention after intratumoral injection in syngeneic mouse tumor models.
29 r, we tested the antitumor activity of local intratumoral injection in the setting of host lymphodepl
30 by serum and ribonucleases in vitro and upon intratumoral injection in vivo, confirming the stability
31 We initially considered three patterns of intratumoral injection in which a fixed fraction of cell
33 vivo and in ex vivo organ analysis following intratumoral injection into HT-1080 xenograft tumors.
34 of STING agonists poses safety issues while intratumoral injection is limited by tumor accessibility
36 d CT26 (H-2(d), colon cancer) murine models, intratumoral injection of 2 x 10(6) AdmCD40L-modified DC
41 ection of breast cancer cells ex vivo and by intratumoral injection of Ad-IRF-1 into established tumo
47 ffect of IGFBP-6 was investigated in vivo by intratumoral injection of Ad5CMV-BP6 in NSCLC xenografts
48 inally, the therapeutic efficacy of a single intratumoral injection of AdCMVCD followed by systemic 5
50 were inoculated into syngeneic C57BL/6 mice, intratumoral injection of adenovirus vector expressing 1
52 ablished MCA205 mouse fibrosarcoma by single intratumoral injection of AdIL-1H4 resulted in significa
55 r toxin from the site of injection following intratumoral injection of AdStx1A1Do and AdStx1A1Ac.
57 ostate cancer, we have previously shown that intratumoral injection of Ag-loaded dendritic cells (DCs
58 tion of endogenous dendritic cells (DCs) and intratumoral injection of Ag-loaded mature DCs delayed t
60 d with allogeneic-IgG-coated tumour cells or intratumoral injection of allogeneic IgG in combination
64 reated intradermal B16F10 murine melanoma by intratumoral injection of an attenuated strain of Toxopl
65 ve this response by combining radiation with intratumoral injection of an IL2-linked tumor-specific a
66 dies, we treated four patients with a single intratumoral injection of an ultralow dose of CAdVEC (NC
68 blished 100-mm3 s.c. tumors who received one intratumoral injection of antibody 38C2 followed by syst
69 ere systemic administration of GM-CSF and/or intratumoral injection of autologous dendritic cells, wh
71 t of tumor-bearing BALB/c mice with a single intratumoral injection of biodegradable polylactic acid
81 we find that enforced activation of STING by intratumoral injection of cyclic dinucleotide GMP-AMP (c
85 the JCI, Zaini et al. report that, in mice, intratumoral injection of DCs genetically modified to ex
86 erapy (cyclophosphamide) combined with local intratumoral injection of DCs led to complete tumor regr
87 n cancer cells accompanied with virotherapy, intratumoral injection of Delta-24-RGDOX and an anti-PD-
89 umor immune modulation can be achieved using intratumoral injection of different immunomodulators dur
93 n in immunodeficient mice, were treated with intratumoral injection of endostatin plasmid at 7-day in
97 e intracerebral tumors generated by GBM-SCs, intratumoral injection of G47Delta significantly prolong
105 ong-term survival analysis demonstrated that intratumoral injection of IL-12 + GM-CSF-loaded microsph
108 Separately, we have shown that a direct intratumoral injection of immunocytokine (IC), an anti-G
112 d radiotherapy delivered selectively through intratumoral injection of lutetium-177 bound to core-cro
117 1(+/-) female mice received a transauricular intratumoral injection of Men1.rAd5 or control treatment
123 lly with GSC005 GBM tumors, and treated with intratumoral injection of oHSV M002 or saline control.
124 del, by the combination of chemotherapy plus intratumoral injection of oligodeoxynucleotides containi
128 red with diluent-treated tumor-bearing mice, intratumoral injection of recombinant ELC/CCL19 led to s
131 or in each animal was accomplished by direct intratumoral injection of retroviral vector-producer cel
132 pe tumors was accomplished in vivo by direct intratumoral injection of retroviral vector-producer cel
136 le avoiding potential issues associated with intratumoral injection of STING agonists, which to date
138 y of conventional chemotherapy together with intratumoral injection of syngeneic bone marrow-derived
143 murine CT26 colon carcinoma model, a single intratumoral injection of the CDA-Mn(2+) PLGA implant in
144 owth and survival studies following a single intratumoral injection of the COVID-19 vaccine showed si
147 f these tumors were significantly reduced by intratumoral injection of the P2X7 inhibitor-oxidized AT
148 sis of P2X7-expressing tumors was blocked by intratumoral injection of the VEGF-blocking antibody Ava
151 ts were observed with local radiotherapy and intratumoral injection of tumor-specific antibodies, ari
153 lytic Ad vector antitumor efficacy following intratumoral injection of vector as well as tumor-to-tis
156 ic CD8 T lymphocytes expanded robustly after intratumoral injection of WT mice with SFV-IL12, this di
157 the brain; however, treatment with a single intratumoral injection of Y10 increased median survival
159 ore, we evaluated the safety and efficacy of intratumoral injections of a bacterial superantigen with
160 neous tumor growth in nude mice who received intratumoral injections of Ad-FHIT, at a total dose of 3
162 re established in nude mice and treated with intratumoral injections of adenoviruses carrying the hum
163 F and anti-c-met U1snRNA/ribozymes by either intratumoral injections of adenoviruses expressing the t
164 ng was conducted in vivo with mice receiving intratumoral injections of AdSSTR2, AdSSTR2-EGFP, or AdE
167 nced transplanted syngeneic tumor were given intratumoral injections of bone marrow-derived dendritic
168 ne to increase the number of tumoral DCs and intratumoral injections of CG-rich motifs (CpGs) to acti
170 ty of using this potent strategy of combined intratumoral injections of DCs and systemic chemotherapy
171 n situ immunomodulation (ISIM) consisting of intratumoral injections of Flt3L to mobilize cDC1s, loca
173 ndent manner that neutralized free VEGF, and intratumoral injections of high-dose GM-CSF ablated bloo
175 a subcutaneous mouse model of human glioma, intratumoral injections of liposomes containing H-ferrit
182 e melanoma model to evaluate the efficacy of intratumoral injections of recombinant NDVs engineered t
184 static A20 lymphoma tumors were treated with intratumoral injections of rF-mCD40L together with syste
188 therapy tests in SCID mice demonstrated that intratumoral injections of the adenoviral vector encodin
189 ontrol groups of tumor-bearing mice received intratumoral injections of the control adenoviral vector
190 teosarcoma and breast cancer, intravenous or intratumoral injections of the probe enabled phosphoresc
191 eived intravenous and intraperitoneal and/or intratumoral injections of TILT-123 as well as intraveno
192 We treated a mouse model of melanoma with intratumoral injections of Toll-like receptor 1/2 (TLR1/
194 The local administration of ICIs through intratumoral injection or peritumoral administration has
195 , [(68)Ga][Ga((III))(PSMA-617)], followed by intratumoral injection or topical application of 20 or 1
196 intravesical injection), brain gliosarcomas (intratumoral injection), or intrathecal gliosarcomas (in
199 Given that viral immunotherapy commonly uses intratumoral injection, prolonging the duration of thera
200 or rapidly drives SCAM differentiation, with intratumoral injections sufficient to instruct naive bon
201 livered with sufficient efficiency by direct intratumoral injection to mediate tumor regression as sh
202 ONYX-015 can be safely administered via intratumoral injection to patients with recurrent/refrac
203 ac damage during therapy and required direct intratumoral injection to yield similar levels of tumor
204 re the effect of introducing CAR T cells via intratumoral injection versus intracavitary administrati
205 dicated that virus administration by U-87 MG intratumoral injection was inadequate, resulting in an e
209 ING-based therapies is the need for frequent intratumoral injections, which hinders patient adherence
218 In addition, our results demonstrated that intratumoral injection with the plasmid construct expres